LLY241206C745000
- 52.39
- 0.000.00%
Eli Lilly and Co Newsroom
Tuesday S&P 500, Nasdaq Pull Back From Highs | Live Stock
Sector Update: Health Care Stocks Decline Premarket Tuesday
Weight Loss Drug Wars Heat Up: Amgen Challenges Eli Lilly, Novo's Dominance
Want To Bet On Ozempic, Wegovy Success? Defiance Introduces Leveraged ETF To Capture Novo Nordisk Momentum
Market Chatter: Novo Nordisk's India Executives Push for Wegovy Launch in 2025
Concerned about falling behind eli lilly and co (LLY.US) and novo-nordisk a/s (NVO.US), the team in india urges to launch Wegovy in india as soon as possible.
Due to concerns about falling behind competitor eli lilly and co in the potentially huge market in india, the indian team of the danish pharmaceutical giant novo-nordisk a/s has been pushing for the earlier launch of its popular weight-loss drug Wegovy in india.
S&P 500 and Nasdaq Hit Closing and Trading Highs Monday | Wall Street Today
December Starts With a Mixed Market | Live Stock
Weight Loss Drugs Like Wegovy, Zepbound Linked To Reduced Alcohol Use: Study
Jefferies Maintains Eli Lilly and Co(LLY.US) With Buy Rating, Maintains Target Price $994
Eli Lilly & Co (LLY) Gets a Buy From Jefferies
Why Is Eli Lilly and Company (LLY) Among Louis Navellier's Top Stock Picks Heading Into 2025?
Eli Lilly and Novo Nordisk's Obesity Moat Just Got Stronger -- Heard on the Street -- WSJ
S&P 500 Posts Weekly Rise to Fresh Record, Ends November With Strongest Monthly Gain of Year
10 Health Care Stocks With Whale Alerts In Today's Session
Behind the Scenes of Eli Lilly's Latest Options Trends
Eli Lilly and Company (LLY) Is a Trending Stock: Facts to Know Before Betting on It
Viking Therapeutics Stock On Brink Of Death Cross As Weight Loss Hype Loses Momentum
Wednesday Ends With Index Decline | Wall Street Today
Short Stock Ideas From Each Sector With Earnings Quality in the Bottom 20%